Selumetinib
Back to searchMolecule Structure
Scientific Name
Selumetinib
Description of the Drug
Selumetinib is a MEK 1/2 inhibitor used in pediatric patients to treat neurofibromatosis type 1 (NF1) accompanied by symptomatic, inoperable plexiform neurofibromas (PN).
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB11689
http://www.drugbank.ca/drugs/DB11689
Brand Name(s)
Not Available
Company Owner(s)
Astrazeneca Pharmaceuticals Lp
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Dual specificity mitogen-activated protein kinase kinase; MEK1/2 | PROTEIN FAMILY | INHIBITOR | CHEMBL2111289 |
| Dual specificity mitogen-activated protein kinase kinase 2 | SINGLE PROTEIN | INHIBITOR | CHEMBL2964 |
| Dual specificity mitogen-activated protein kinase kinase 1 | SINGLE PROTEIN | INHIBITOR | CHEMBL3587 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL155456 | |
| PharmGKB | PA166129529 | |
| Human Metabolome Database | HMDB0304858 | |
| DrugBank | DB11689 | |
| PubChem: Thomson Pharma | 15117183 | |
| PubChem | 10127622 | |
| Mcule | MCULE-8405743860 | |
| LINCS | LSM-1056 | |
| Nikkaji | J2.516.155F | |
| PDBe | 3EW | |
| BindingDB | 50355497 | |
| EPA CompTox Dashboard | DTXSID3048944 | |
| DrugCentral | 5388 | |
| Brenda | 217796 | 155505 |
| ChemicalBook | CB81871940 | |
| Guide to Pharmacology | 5665 | |
| rxnorm | SELUMETINIB SULFATE | SELUMETINIB |
| ChEBI | 90227 | |
| ZINC | ZINC000031773258 |
